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Abstract We here cloned a cDNA encoding STAM2, a new
member of the STAM family, which contains an SH3 domain
and ITAM. STAM2 like STAM1 is associated with Jak2 and
Jak3, and involved in the signaling for DNA synthesis and c-myc
induction mediated by IL-2 and GM-CSF. Co-expression of the
SH3 deletion mutants of STAM1 and STAM2 induces an
additive effect on suppressing DNA synthesis upon stimulation
with IL-2 and GM-CSF, suggesting that STAM1 and STAM2
exhibit compensatory effects on the signaling pathways down-
stream of Jak2 and Jak3 upon stimulation with GM-SCF and
IL-2, respectively. ß 2000 Federation of European Biochemi-
cal Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
The Qc chain is a common receptor subunit for cytokines
such as interleukin 2 (IL-2), IL-4, IL-7, IL-9 and IL-15, and
its mutations cause X-linked severe combined immunode¢-
ciency, characterized as a profound defect of T and NK cells
and impairment of B cell di¡erentiation in humans and mice
[1]. The Lc chain is a common receptor subunit for cytokines
such as IL-3, IL-5 and granulocyte/macrophage colony stim-
ulating factor (GM-CSF) [2]. The cytoplasmic portions of the
Qc and Lc chains are associated with Janus kinase 3 (Jak3) and
Jak2, respectively [3,4]. Stat5 is reportedly involved in the
signal transduction immediately downstream of Jak3 and
Jak2, and translocated to the nucleus upon stimulation with
the respective cytokines [5]. Stat5 activated by Jak2 has been
shown to contribute to the signaling for DNA synthesis medi-
ated by IL-3 [6]. However, there have been some controversial
reports regarding the involvement of Stat5 in cell growth sig-
naling mediated by Jak3 upon stimulation with IL-2; T cells
derived from Stat5A/B double knockout mice do not retain
ability for IL-2-induced cell growth [7], whereas T cells ex-
pressing the IL-2 receptor L chain mutant which lacks the
Stat5 binding site show no activation of Stat5 upon IL-2
stimulation, are responsive to a higher dose of IL-2 to pro-
liferate [8]. The cytokines sharing the Qc and Lc chains induce
expression of proto-oncogenes such as c-myc, c-fos and c-jun,
and the induction of c-fos/c-jun requires activation of Ras [9].
Although the phosphatidylinositol 3 kinase-Akt pathway is
reportedly involved in IL-2-mediated c-myc induction [10],
little is known about the c-myc inducing pathway immediately
downstream of Jak3 in IL-2 signaling.
We recently identi¢ed a phosphotyrosine protein named
STAM (signal transducing adapter molecule), which has a
unique structure containing an Src homology 3 (SH3) domain
and a tyrosine cluster region including an immunoreceptor
tyrosine-based activation motif (ITAM) [11], and found that
STAM is associated with Jak3 and Jak2 [12]. Transfection
with the SH3 deletion mutant of STAM induced a reduction
of DNA synthesis mediated by IL-2 and GM-CSF, and trans-
fection of the wild-type STAM but not the STAM mutants
deleted of the SH3 and ITAM, enhanced c-myc induction
upon stimulation with IL-2 and GM-CSF, demonstrating
the involvement of STAM in signaling for DNA synthesis
and c-myc induction mediated by IL-2 and GM-CSF [12]. A
variety of cytokines and growth factors such as IL-2, IL-4, IL-
7, IL-3, GM-CSF, platelet-derived growth factor (PDGF) and
epidermal cell growth factor (EGF) induced tyrosine phos-
phorylation of STAM, and STAM was expressed ubiquitously
among a variety of tissues tested, suggesting a potential im-
plication of STAM in signaling pathways from a variety of
cytokine receptors [11].
We here cloned a cDNA encoding a new member of the
STAM family, STAM2, and demonstrated that STAM2 as
well as STAM1, the original STAM, is involved in the signal-
ing for DNA synthesis and c-myc induction upon stimulation
with IL-2 and GM-CSF.
2. Materials and methods
2.1. Cells
Cell lines used were human MOLT-4, ILT-Mat, TF-1, Daudi,
HeLa and 293T, and a simian ¢broblastoid COS7. MOLTL is a
MOLT-4 subline stably transfected with the human IL-2 receptor L
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chain [13]. HepG2/PDGFR is a HepG2 subline stably transfected with
cDNA of PDGFL receptors [14]. BAF-B03, a mouse IL-3-dependent
pro-B cell line, was maintained in RPMI 1640 medium supplemented
with 10% fetal calf serum, 10% WEHI-3 conditioned medium contain-
ing IL-3 and 2-mercaptoethanol.
2.2. Plasmid constructs
The wild-type STAM2 and its mutants were inserted into pCXN2
expression vectors at the XhoI site [15]. STAM2 mutants include
2DSH3 deleted of the SH3 domain (amino acid position Ala209^
Val256), 2DIT deleted of the ITAM region (amino acid position
Glu349^Leu377) and 2DY2 deleted of the C-terminal half (amino
acid position Lys343^Leu525). Expression plasmids for the wild-type
and mutants of STAM1 such as DSH3, DIT and DY2 were described
previously [12]. The wild-type and mutants of STAM1 and STAM2
were subcloned into pcDNA3.1/V5-His (Invitrogen) for V5-tagging at
their C-termini. Expression plasmids for Jak1 and Tyk2 were
pRK5mJak1 and pRK5hTyk2, respectively [16].
2.3. Luciferase assay
Luciferase assays for c-myc promoter activities were performed as
described previously [12]. In brief, BAF-B03 cells were incubated in
the absence of IL-3 for 12 h, and then transiently transfected with
expression plasmids for human IL-2 receptor L and Qc, or GM-CSF
receptor K and Lc, together with STAMs, L-galactosidase reporter and
c-myc promoter-driven luciferase reporter plasmids. The cells were
then stimulated with 10 nM human recombinant IL-2 (provided
from Ajinomoto Co., Japan) or with 20 ng/ml human recombinant
GM-CSF for 6 h, and assayed for luciferase and L-galactosidase ac-
tivities.
2.4. Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were carried out as de-
scribed previously [17]. Brie£y, cells were lysed with cell extraction
bu¡er (1% NP-40, 20 mM Tris^HCl pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl £uoride and 20
Wg/ml aprotinin). The cell lysates were immunoprecipitated with in-
dicated antibodies (Abs), and the immunoprecipitates were then sep-
arated by SDS^PAGE and transferred to PVDF ¢lters (Millipore,
Japan). After blocking with phosphate-bu¡ered saline containing 3%
bovine serum albumin and 0.1% Tween 20, the ¢lters were probed
with indicated Abs and visualized by using the ECL detection system
(Amersham, UK).
3. Results
3.1. Cloning of human STAM2
By screening the expression sequence tag database, we
found a sequence highly homologous to the human STAM
gene from a human fetal brain cDNA library (GenBank ac-
cession number M78581). Based on this information, we pre-
pared a cDNA probe, and isolated a human cDNA clone with
3.9 kbp from a cDNA library of human phytohemagglutinin-
stimulated peripheral blood leukocytes. The 3.9 kbp cDNA
clone contains an open reading frame encoding a protein with
525 amino acids, which corresponds to the full length of
STAM, containing an SH3 domain and tyrosine cluster region
including an ITAM. Hence, we renamed STAM as STAM1,
and termed the newly cloned STAM homologous molecule as
STAM2. The GenBank accession number of the human
STAM2 is AF042273. Amino acid sequence homologies be-
tween STAM1 and STAM2 were 50.1% in the whole, 71.9%
in the N-terminal half, 89.4% in the SH3 domain and 41.7% in
the C-terminal portion including the ITAM. Chicken EAST
and mouse Hbp were recently cloned, and found to be ho-
mologous to STAM1 [18,19]. Our homology search of the
protein databases showed that overall similarities of EAST
and Hbp are 47.0% and 56% with STAM1, respectively, and
69.0% and 86% with STAM2, respectively, suggesting that
Fig. 1. Cytokine-induced tyrosine phosphorylation of STAMs. MOLTL, TF-1, HeLa and HepG2/PDGFR cells were stimulated for 10 min
with IL-2, GM-CSF, EGF and PDGF, respectively. Their lysates were then immunoprecipitated with anti-STAM2 Ab or preimmune rabbit se-
rum as control, and immunoblotted with anti-phosphotyrosine monoclonal Ab (mAb) or anti-STAM2 Ab.
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STAM2 may be the human homolog of chicken EAST and
mouse Hbp.
Northern blot and immunoblot analyses revealed that
STAM2 is ubiquitously expressed among a variety of human
tissues and cell lines with three mRNA sizes of 1.3 kb, 3.9 kb
and 6.8 kb, and 68 kDa molecular mass, respectively (data not
shown).
3.2. Tyrosine phosphorylation of STAM2
Since STAM1 has been shown to be tyrosine-phosphorylat-
ed upon stimulation with a wide variety of cytokines [11], we
examined the tyrosine phosphorylation of STAM2 in re-
sponses to several cytokines. MOLTL, TF-1, HeLa and
HepG2/PDGFR cells were stimulated with IL-2, GM-CSF,
EGF and PDGF, respectively, for 10 min, their lysates were
then immunoprecipitated with anti-STAM2 Ab followed by
immunoblotting with anti-phosphotyrosine and anti-STAM2
Abs. The tyrosine phosphorylation of STAM2 was detected
after treatment with all these cytokines (Fig. 1). Tyrosine
phosphorylation of STAM2 was seen within 5 min of IL-2
stimulation, became maximal at 10 min and then gradually
decreased (data not shown).
3.3. Association of STAM2 with the Jak family tyrosine
kinases
Since STAM1 is associated with Jak3 and Jak2 via its
ITAM region [12], we examined whether STAM2 is also as-
sociated with the Jaks by carrying out co-immunoprecipita-
tion studies. IL-2-dependent ILT-Mat cells, GM-CSF-depen-
dent TF-1 cells and IFN-K-responsive Daudi cells were
Fig. 2. Co-immunoprecipitation of STAM2 with the Jak family members and Lck. ILT-Mat (A, C, E), TF-1 cells (B) and Daudi cells (D) were
incubated for 10 min in the presence (+) or absence (3) of 10 nM IL-2, 20 ng/ml GM-CSF and 0.1 ng/ml IFN-K, respectively. Their lysates
were immunoprecipitated with anti-STAM2 Ab (lanes 2 and 3), preimmune rabbit serum as a control (lane 1), anti-Jak3 (A, lanes 4^8), anti-
Jak2 (B, lanes 4^8), anti-Jak1 (C, lanes 4^8), anti-Tyk2 (D, lanes 4^8) and anti-Lck Ab (E, lanes 4^8). The immunoprecipitates were separated
by SDS^PAGE and blotted with anti-Jak3, anti-Jak2, anti-Jak1, anti-Tyk2, anti-Lck Ab and anti-phosphotyrosine mAb (lanes 5^8) (upper
blots), or with anti-STAM2, anti-Jak3, anti-Jak2, anti-Jak1, anti-Tyk2 and anti-Lck Ab (lower blots). (F) 293T cells were transfected with (+)
or without (3) 2 Wg each of expression plasmids for STAM2, Jak1 and Tyk2 by the calcium-phosphate method, and their lysates were immu-
noprecipitated with anti-STAM2 Ab followed by immunoblotting with anti-Jak1, anti-Tyk2 (upper blots) and anti-STAM2 Ab (lower blots).
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Fig. 3. Determination of the binding sites of Jak3 for STAM2, and of STAM2 for Jak3 and Jak2. (A) A schematic representation of the Jak3
mutants. The numbers indicate positions of the C-terminal or N-terminal amino acid residues of the Jak3 mutants. (B, C) Determination of
the binding site of Jak3 for STAM2. COS7 cells were transfected with 10 Wg each of the wild-type and mutant cDNAs of Jak3 together with
V5-tagged wild-type STAM2. Their lysates were immunoprecipitated with anti-V5 mAb and immunoblotted with anti-Jak3 N-terminus (N; N-
15: Santa Cruz) Ab (B, C), anti-Jak3 C-terminus Ab (C; C-21: Santa Cruz) (C) and anti-V5 mAb. (D, E) Determination of the binding site of
STAM2 for Jak3 and Jak2. COS7 cells were transiently transfected with 20 Wg each of V5-tagged wild-type STAM2 (STAM2-V5), SH3-deleted
STAM2 mutant (V5-2DSH3), ITAM-deleted STAM2 mutant (V5-2DIT) and C-terminus half-deleted mutant STAM2 (V5-2DY2) plasmids or
empty vector (pcDNA3.1-HisA-V5; Invitrogen) as control, together with 10 Wg of Jak3 (D) or Jak2 plasmid (E). The cells were incubated for
48 h, and their lysates were immunoprecipitated with anti-V5 mAb and then immunoblotted with anti-Jak3 or anti-Jak2 and anti-V5 Abs.
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stimulated with IL-2, GM-CSF and IFN-K, respectively, and
their lysates were precipitated with anti-STAM2 Ab followed
by immunoblotting with anti-Jak3, anti-Jak2, anti-Jak1, Tyk2
or anti-Lck Abs. STAM2 was signi¢cantly co-immunopreci-
pitated with Jak3 and Jak2 irrespective of ligand stimulation
(Fig. 2A,B), but not with Jak1, Tyk2 or Lck (Fig. 2C^E).
Tyrosine phosphorylation of the Jaks and Lck was signi¢-
cantly induced or increased after ligand stimulation (Fig. 2),
indicating that the cells were responded to the ligands. Since
the expression levels of Jak1 and Tyk2 were much lower than
those of Jak3 and Jak2, we performed co-immunoprecipita-
tion studies using 293T cells exogenously introduced with ex-
pression plasmids for STAM2, Jak1 and Tyk2. Both Jak1 and
Tyk2 were apparently co-immunoprecipitated with STAM2 in
their lysates (Fig. 2), indicating that STAM2 is able to bind to
Jak1 and Tyk2 irrespective of ligand stimulation in cells ex-
pressing su⁄cient amounts of STAM2, Jak1 and Tyk2.
The binding site of Jak3 to STAM1 and STAM2 was de-
termined by using Jak3 mutants [20] (Fig. 3A). The wild-type
Jak3, J3(StuI) mutant and J3(MunI) mutant were co-immu-
noprecipitated with STAM2, whereas J3(vJH7) mutant was
not (Fig. 3B,C). Similar results were obtained in co-immuno-
precipitation between the Jak3 mutants and STAM1 (data not
shown), suggesting that STAM1 and STAM2 could interact
with the same binding site located at the JH7 region of Jak3.
We also revealed that STAM2 like STAM1 binds to Jak2 and
Jak3 through its ITAM region (Fig. 3D).
3.4. Involvement of STAM2 in c-myc induction mediated by
IL-2 and GM-CSF
Next, we examined the e¡ect of STAM2 on the cytokine-
mediated signaling for the induction of proto-oncogenes such
as c-myc and c-fos by using luciferase reporter gene assays
with BAF-B03 cells. BAF-B03 cells transfected with the
wild-type STAM2 showed a 6-fold increase of c-myc luciferase
activity upon IL-2 stimulation compared to a barely 2.7-fold
increase with the control vector, whereas the transfectant cells
with 2DSH3, 2DIT and 2DY2 mutants of STAM2 showed
similar increases to the control vector (Fig. 4A). The enhance-
ment of IL-2-mediated c-myc induction was dose-dependent
on the wild-type STAM2 plasmid (Fig. 4B). Similar results
were obtained with the GM-CSF stimulation system (data
not shown). These results indicate that wild-type STAM2 po-
tentiates c-myc induction mediated by IL-2 and GM-CSF,
suggesting the involvement of STAM2 in signal transduction
for c-myc induction mediated by these cytokines. Both the
SH3 domain and ITAM of STAM2 seem essential for such
signal transduction.
The wild-type STAM2 conferred marginal e¡ects on c-fos
promoter-driven luciferase activities mediated by IL-2 and
GM-CSF (data not shown).
3.5. The SH3 deletion mutant of STAM2 confers a
dominant-negative e¡ect on DNA synthesis mediated by
IL-2 and GM-CSF
To investigate the functional signi¢cance of STAM2 in cell
growth signaling mediated by cytokines, BAF-B03 cells were
transiently transfected with the wild-type and mutants of
STAM2 together with the human IL-2 receptor L and Qc
chains, and assayed for DNA synthesis after 24 h stimulation
with IL-2. The BAF-B03 cells transfected with the control
vector showed a signi¢cant increase of [3H]thymidine incor-
poration, comparable with the transfectants containing the
wild-type, 2DIT and 2DY2, whereas transfection with
2DSH3 induced 47.0% suppressions of [3H]thymidine uptake
upon stimulation with IL-2 (Fig. 5A). The suppression of IL-
2-induced [3H]thymidine uptake was dose-dependent on
2DSH3 plasmids (Fig. 5B). Similar results were obtained
with the GM-CSF stimulation system; the 2DSH3 induced
a signi¢cant suppression of GM-CSF-induced [3H]thymidine
uptake (data not shown). The degree of suppression of IL-2-
induced [3H]thymidine uptake by 30 Wg of the SH3 deletion
mutant of STAM1 (DSH3) alone was the same as that in-
duced by 15 Wg each of DSH3 and 2DSH3 together (Fig.
5C), indicating that there is an additive e¡ect but not syner-
gistic e¡ect between the SH3-deleted mutants of STAM1 and
STAM2 on IL-2-induced [3H]thymidine uptake. These results
suggest that both STAM1 and STAM2 contribute to the cell
growth signaling mediated by IL-2 and GM-CSF through
their similar mechanisms.
Fig. 4. E¡ects of STAM1 and STAM2 on induction of c-myc in re-
sponse to IL-2. BAF-B03 cells deprived of IL-3 for 12 h were trans-
fected with expression plasmids for the wild-type STAM1
(pCXSTAM1), the wild-type STAM2 (pCXSTAM2), 2DSH3 mu-
tant (pCX2DSH3), 2DIT mutant (pCX2DIT), 2DY2 mutant
(pCX2DY2) and empty vector (pCXN2) (A), or with combinations
of pCXSTAM2 and pCXN2 (B), together with human IL-2 receptor
L and Qc plasmids, in addition to luciferase reporter plasmid con-
taining c-myc promoter (pHXLuc) and plasmid for L-galactosidase
(pENL) by electroporation. Subsequently, the cells were stimulated
for 6 h with (+) or without (3) human recombinant IL-2 (A and
B). The luciferase activities were displayed after correction of pro-
tein concentration and L-galactosidase activity of cell lysates. The
values shown are means þ S.E.M. of triplicate determinants. Results
represent one of three comparable experiments.
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4. Discussion
The present study documents the presence of transcripts
encoding a new STAM1 homologous molecule, named
STAM2. STAM2 was revealed to have similar characteristics
to STAM1 in its ubiquitous expression among a variety of
human tissues and cell lines. In addition, STAM2 contains
an SH3 domain and tyrosine cluster region including an
ITAM in its structure, is associated with Jak2 and Jak3,
and tyrosine-phosphorylated upon stimulation with cytokines
and growth factors, such as IL-2, GM-CSF, EGF and PDGF
in a similar manner to STAM1 [11]. These observations sug-
gest that a functional similarity between STAM1 and STAM2
exists.
The IL-2 receptor Qc and GM-CSF receptor Lc chains are
associated with Jak3 and Jak2, respectively [3,4]. These ki-
nases are indispensable for signal transduction for cell growth
and in the induction of proto-oncogenes such as c-myc and c-
fos [3,21]. The ITAMs of STAM1 and STAM2 were shown to
both bind to the JH7 region of Jak3, suggesting that STAM1
Fig. 5. The SH3 deletion mutant of STAM2 induces suppression of [3H]thymidine incorporation mediated by IL-2. BAF-B03 cells maintained
in the medium containing IL-3 were transfected with 15 Wg each of pCXSTAM2, pCX2DSH3, pCX2DIT, pCX2DY2 and pCXN2, together
with human IL-2 receptor L and Qc plasmids. They were cultured for 24 h with (+) or without (3) IL-2, and assayed for [3H]thymidine incor-
poration for the last 4 h cultivation. (B) pCX2DSH3 dose-dependent suppression of [3H]thymidine incorporation mediated by IL-2.
[3H]thymidine incorporation assays were carried out in a similar manner to (A) with the indicated doses of pCX2DSH3. (C) An additive e¡ect
between the SH3 deletion mutants of STAM1 and STAM2 on suppression of [3H]thymidine incorporation mediated by IL-2. BAF-B03 cells
were transfected with the indicated plasmids together with 2 Wg of human IL-2 receptor L and Qc plasmids by electroporation, and were assayed
for [3H]thymidine incorporation in a similar manner to (A). The values shown are means þ S.E.M. of triplicate cultures. Results represent one
of three comparable experiments.
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and STAM2 bind to the same site on Jak3. This fact was
further re£ected in the observation that STAM1 and
STAM2 are competitive in their binding to Jak3 (data not
shown). Although the JH7 region of Jak3 is known to include
the binding site for the Qc chain, the Qc binding site of Jak3
may be distinct from the binding site for the STAMs because
the J3(MunI) mutant of Jak3 binds to the STAMs but not the
Qc chain [20]. Co-immunoprecipitation studies did not detect
an association of native STAM2 with native Jak1 and Tyk2,
however overexpression of Jak1 and Tyk2 along with STAM2
in 293T cells induced a signi¢cant association of STAM2 with
both Jak1 and Tyk2, suggesting that STAM2 is able to bind
to all the Jak family members. Since the amino acid sequence
alignments of the JH7 regions of the Jak family proteins in-
dicate that Jak3 is more homologous to Jak2 than Jak1 or
Tyk2 [22,23], we suspect that the binding a⁄nities of Jak3 and
Jak2 to the STAMs may be stronger than those of Jak1 and
Tyk2.
We here provided evidence for involvement of STAM2 in
signal transduction mediated by IL-2 and GM-CSF. Overex-
pression of the wild-type STAM2 induced an enhancement of
c-myc induction mediated by IL-2 and GM-CSF, whereas
STAM2 mutants deleted of the SH3 domain and ITAM lost
this ability. Similar e¡ects on the cytokine-mediated c-myc
induction were seen with STAM1 [12]. On the other hand,
not only the SH3-deleted STAM1 mutant, but also the
SH3-deleted STAM2 mutant induced signi¢cant reductions
of [3H]thymidine incorporation upon stimulation with IL-2
and GM-CSF. Furthermore, simultaneous transfection of
the SH3-deleted mutants of STAM1 and STAM2 induced
an additive e¡ect on the reduction of [3H]thymidine incorpo-
ration, suggesting that STAM1 and STAM2 contribute to the
cytokine-mediated signal transduction at a similar position
downstream of Jak2 and Jak3. Taken together, we suspect
that STAM1 and STAM2 have compensatory functions
with each other in the signal transduction for cytokine-medi-
ated DNA synthesis and c-myc induction.
We previously cloned a cDNA encoding a novel molecule
named AMSH, which is associated with the SH3 domain of
STAM1 and possibly involved in signaling for c-myc induc-
tion and DNA synthesis mediated by IL-2 and GM-CSF [24].
We have con¢rmed that STAM2 is co-immunoprecipitated
with AMSH after DSP chemical cross-linking (data not
shown), suggesting the complexes of STAM1 and STAM2
with AMSH play important roles in the signal transduction
mediated by these cytokines.
The amino acid sequence comparison revealed that STAM2
is a human homologue of chicken EAST and mouse Hbp.
EAST was shown to bind to the EGF receptor upon EGF
stimulation and to co-localize with clathrin through associa-
tion with Eps15 [18]. Hbp was also found to be involved in
the intracellular degradation of PDGF and its receptor [19].
These observations together with the present study suggest
that the STAM family proteins are involved in regulation of
not only intracellular signal transduction mediated by cyto-
kines and growth factors but also receptor-mediated endocy-
tosis.
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